Comparative Analysis of Amphotericin B Lipid Complex and Liposomal Amphotericin B Kinetics of Lung Accumulation and Fungal Clearance in a Murine Model of Acute Invasive Pulmonary Aspergillosis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The reformulation of amphotericin B (AMB) into a lipid complex (AMB lipid complex [ABLC]) or liposomal carrier (liposomal AMB [L-AMB]) changes the rate and extent of drug distribution to the lung. The importance of pharmacokinetic differences among the various lipid AMB formulations in the treatment of invasive pulmonary aspergillosis (IPA) remains unknown. We compared the kinetics of AMB lung accumulation and fungal clearance of ABLC- and L-AMB-treated mice with acute IPA. BALB/c mice were immunosuppressed with cyclophosphamide and cortisone before intranasal inoculation with 1.5 × 10 6 Aspergillus fumigatus 293 conidia. ABLC or L-AMB was administered in daily intravenous doses (1, 5, or 10 mg/kg of body weight), starting 12 h after infection and continuing until day 5. At predetermined times (0, 24, 72, and 120 h), mice were euthanized, and lungs were harvested for determinations of lung fungal burdens (quantitative PCR) and total AMB lung tissue concentrations. Both ABLC and L-AMB were effective at reducing lung fungal burdens at doses of ≥5 mg/kg/day. Clearance of A. fumigatus during the first 24 h was associated with AMB tissue concentrations of >4 μg/g. At 5 mg/kg/day, ABLC produced a more rapid fungal clearance than did L-AMB, but at the end of therapy, fungal burden reductions were similar for both formulations and were not improved with higher dosages. These data suggest that ABLC delivers active AMB to the lung more rapidly than does L-AMB, resulting in faster Aspergillus clearance in an experimental model of IPA. However, pharmacodynamic differences between the two formulations were less apparent when mice were dosed at 10 mg/kg/day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus
Nierman, W. C., Pain, A., Anderson, M. J., Wortman, J. R., Kim, H. S., Arroyo, J., Berriman, M., Abe, K., Archer, D. B., Bermejo, C., et al. (2005) · Nature · doi:10.1038/nature04332 · Cited by 1,391
Ostrosky-Zeichner, L., Alexander, B. D., Kett, D. H., Vazquez, J., Pappas, P. G., Saeki, F., Ketchum, P. A., Wingard, J., Schiff, R., Tamura, H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432470 · Cited by 669 · cited 1×
“1% in patients with proven 10 infections when the 60 pg/mL cutoff value is used to define sample positivity (23).”
MethodPfaller, M. A., Sheehan, D. J., & Rex, J. H. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.268-280.2004 · Cited by 352 · cited 1×
“determining the mean fungicidal concentration (MFC) for filamentous fungi (24).”
BackgroundBalloy, V., Huerre, M., Latgé, J.-P., & Chignard, M. (2005) · Infection and Immunity · doi:10.1128/iai.73.1.494-503.2005 · Cited by 231
Aspergillosis: Spectrum of Disease, Diagnosis, and Treatment
Barnes, P. D., & Marr, K. A. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.06.001 · Cited by 205 · cited 1×
“3 Despite the availability of new treatment options, lipid formulations of amphotericin B 1 regimens continue to play a central role in the management of invasive pulmonary aspergillosis 2 (IPA) due to their broad spectrum and low potential for cross-resistance with other antifungals (5).”
BackgroundLewis, R. E., Wiederhold, N. P., & Klepser, M. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.945-951.2005 · Cited by 129
Self-citationAndes, D., Safdar, N., Marchillo, K., & Conklin, R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.674-684.2006 · Cited by 116
Cited by
Moen, M. D., Lyseng-Williamson, K. A., & Scott, L. J. (2009) · Drugs · doi:10.2165/00003495-200969030-00010 · Cited by 321
Antifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134
“There are numerous additional analyses that include PK and outcome (Janknegt et al. 1992; Groll et al. 2006; Lewis et al. 2007; Bradley et al. 2010).”
BackgroundInvasive fungal infections in acute leukemia
Bhatt, V. R., Viola, G. M., & Ferrajoli, A. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711410098 · Cited by 71
Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
Lepak, A., & Andes, D. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.001 · Cited by 62
Metadata
- Authors
- Lewis, R. E., Liao, G., Hou, J., Chamilos, G., Prince, R. A., & Kontoyiannis, D. P.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2007-04
- Volume
- 51
- Issue
- 4
- Pages
- 1253-1258
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2102745741
- Cited by
- 69
- References
- 7
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative Analysis of Amphotericin B Lipid Complex and Liposomal Amphotericin B Kinetics of Lung Accumulation and Fungal Clearance in a Murine Model of Acute Invasive Pulmonary Aspergillosis. https://app.cochat.ai/papers/10.1128/aac.01449-06
- The paper
- Lewis, R. E., Liao, G., Hou, J., Chamilos, G., Prince, R. A., & Kontoyiannis, D. P. (2007). Comparative Analysis of Amphotericin B Lipid Complex and Liposomal Amphotericin B Kinetics of Lung Accumulation and Fungal Clearance in a Murine Model of Acute Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01449-06
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.